Targeted Oncology Staff

Clinicians weigh acalabrutinib vs zanubrutinib for relapsed CLL, focusing on adverse effects, trial data, and where pirtobrutinib fits next.

During a virtual event, Eric K. Singhi, MD, and participants discussed how the ROS1 G2032R resistance mutation is guiding second-line therapy selection in ROS1-positive advanced non–small cell lung cancer.

The application for the selinexor combination is supported by data from the phase 3 SENTRY trial.

August 2026 FDA oncology updates: iberdomide, zanidatamab, and daraxonrasib win approvals as fast-track designations accelerate targeted pipelines.

The approval marks the first new agent specifically approved for essential thrombocythemia in the US in nearly 30 years.

ASCO's updated guideline on breast cancer follow-up recommends risk-based surveillance intensity and selective mammography rather than one-size-fits-all follow-up.

Almost one-third of patients became newly eligible for treatment after identification of a previously undetected druggable mutation.

During a live event, Casey L. O'Connell, MD, and participants considered how white blood cell count may factor into risk assessment for polycythemia vera.

Celcuity seeks FDA expansion for gedatolisib combos in PIK3CA-mutant HR+/HER2– metastatic breast cancer, after VIKTORIA-1 shows longer PFS than alpelisib.

ERAS-0015 is being tested in AURORAS-1, an open-label study enrolling patients with RAS-mutant solid tumors.

The assays are now approved to assess HER2 status in gastric, gastroesophageal junction, and esophageal adenocarcinoma.

The final recommendations were directly shaped by data from 36 published articles.

The FDA approved 2 zanidatamab-based regimens for first-line HER2-positive gastroesophageal adenocarcinoma, based on phase 3 HERIZON-GEA-01 data.

Adding radium-223 to cabozantinib did not improve skeletal event-free survival in the phase 2 RADICAL trial of renal cell carcinoma with bone metastases.

Second-line platinum plus pemetrexed produced an 11.5-month median OS and 72% disease control after first-line nivolumab/ipilimumab in pleural mesothelioma.

Experts weigh continuous vs time‑limited CLL therapy, compare acalabrutinib and zanubrutinib, and debate when pirtobrutinib fits first line.

Two peer-reviewed publications cite ProSense cryoablation FDA authorization and ASBrS guidelines, and extend its use to axillary lymph node disease.

During a live Case-Based Roundtable event, Brea Lipe, MD, and participants discussed how aggressively to bridge a CAR T-eligible patient with high-risk relapsed myeloma.

The FDA has granted fast track designation to safusidenib, an oral IDH1 inhibitor, based on durable phase 2 J201 study responses in IDH1-mutant glioma.

The FDA has granted breakthrough therapy and fast track designations to 68Ga-NYM096, a PET imaging agent for clear cell renal cell carcinoma.

The FDA has granted fast track designation to PLN-101095 plus pembrolizumab for ICI-refractory advanced or metastatic solid tumors.

During a Community Case Forum event, Manojkumar Bupathi, MD, MS, and participants discussed how drug interactions, cost, and day-to-day tolerability are what separate one ARPI regimen from another in hormone-sensitive prostate cancer.

The FDA has granted fast track designation to BH-30643, an oral OMNI-EGFR inhibitor, for advanced EGFR C797S-positive non–small cell lung cancer after a third-generation TKI.

The FDA has granted fast track designation to ETX-19477, an oral PARG inhibitor, for BRCA-mutated, HR+/HER2– unresectable or metastatic breast cancer.

During a live event, Sudarsan Kollimuttathuillam, MD, and participants discussed how real-world practice for preventing febrile neutropenia in extensive-stage small cell lung cancer often runs ahead of formal risk stratification.

The designation is for sapanisertib/serabelisib (Piktor) plus chemo in patients who have progressed after chemo and an immune checkpoint inhibitor.

AstraZeneca is discontinuing the phase 3 eVOLVE-Lung02 trial after finding volrustomig plus chemotherapy unlikely to meet its primary end points in metastatic NSCLC.

Trastuzumab deruxtecan improved progression-free survival vs chemoimmunotherapy in the phase 3 DESTINY-Lung04 trial in HER2-mutant NSCLC.

Savolitinib plus osimertinib met PFS and OS end points vs chemotherapy in the phase 3 SAFFRON trial of EGFR-mutated, MET-driven NSCLC.

The multicenter PRO B trial found that weekly ePRO monitoring with alert-based nurse contact reduced fatigue vs usual care in metastatic breast cancer.